In that regard, TCR-pMHC binding avidity (i.e., koff or off-rates) can be viewed as a key T-cell-based biomarker for assessing the functional quality of CD8 T-cells in well-defined clinical settings, such as therapeutic vaccination, helping determine the potency of anti-tumor T-cell responses (34, 37). This evidence concerns the gene CD8A and neoplasm.